PT-141 is a name used for bremelanotide, the active ingredient in Vyleesi. Its US label addresses acquired, generalized hypoactive sexual desire disorder in eligible premenopausal women, rather than general sexual-performance enhancement.
What the research shows
The Vyleesi label excludes low desire explained by other medical or psychiatric conditions, relationship problems or medicines. It does not indicate use in men or postmenopausal women. These limits matter when describing the substance. [1]
Distinguishing substances and products
A PT-141 label alone does not establish that a vial is Vyleesi or has the same approval. Manufacturer, formulation and product registration need separate verification. Melanotan II findings are not interchangeable with bremelanotide evidence.
Reading a specific brand’s label
Start with the exact substance and product name, then match the label to the manufacturer’s documents. This article does not establish Thai registration or current availability for an unspecified product.
Frequently asked questions
Is every PT-141 product Vyleesi?
No. A shared substance name does not establish product identity.
Is Vyleesi indicated for general sexual-performance enhancement?
No. The cited label defines a specific HSDD patient population.
What information helps identify a specific product?
The brand, product name, full label and matching manufacturer documents. Evidence about the substance alone does not establish a product’s identity, registration or quality.
Related information
For general questions about names or label details, contact LINE: @musclestationth
Sources and review date
Sources checked: 11 September 2026. This page explains selected primary sources; it is not a systematic review of every study.